Versant Venture Management LLC Acquires Shares of 12,166,109 Century Therapeutics, Inc. $IPSC

Versant Venture Management LLC bought a new position in Century Therapeutics, Inc. (NASDAQ:IPSC) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 12,166,109 shares of the company’s stock, valued at approximately $27,495,000. Century Therapeutics makes up 19.4% of Versant Venture Management LLC’s investment portfolio, making the stock its 2nd largest position. Versant Venture Management LLC owned about 0.07% of Century Therapeutics at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Bank of America Corp DE lifted its position in shares of Century Therapeutics by 109.1% in the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after acquiring an additional 34,466 shares in the last quarter. AQR Capital Management LLC grew its position in Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after purchasing an additional 86,875 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after purchasing an additional 38,052 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Century Therapeutics by 101.2% in the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after purchasing an additional 142,953 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new stake in shares of Century Therapeutics in the second quarter valued at $25,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 27th. HC Wainwright boosted their target price on Century Therapeutics from $2.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Finally, Mizuho began coverage on Century Therapeutics in a research report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.75.

Century Therapeutics Stock Up 1.9%

IPSC opened at $2.17 on Thursday. The stock’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $2.16. The firm has a market capitalization of $391.37 million, a P/E ratio of -1.90 and a beta of 1.55. Century Therapeutics, Inc. has a 12-month low of $0.44 and a 12-month high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Wednesday, May 13th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. As a group, analysts anticipate that Century Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Century Therapeutics Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.